



An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over This study is NOT accepting healthy

volunteers

Inclusion Criteria:

- confirmed locally advanced unresectable or metastatic urothelial cancer (UC) including that originating from the renal pelvis, ureters, bladder, or urethra - able to receive cisplatin- or carboplatin-containing chemotherapy - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- history of or active autoimmune disease that has required systemic treatment in the past 2 years - prior solid organ or bone marrow transplantation - pleural effusion or ascites with symptoms or requiring symptomatic treatment

Conditions & Interventions

Conditions:

Cancer

Keywords:

Urothelial Carcinoma

More Information

Description: We're studying disitamab vedotin to find out what its side effects are and if it works for urothelial cancer when given with pembrolizumab. We want to see if these drugs work better together than the available approved treatments.

Study Contact: Halle Isom - halle.isom@fairview.org

Principal Investigator: Gautam Jha

IRB

Number: STUDY00018433

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance